8(R)-HPODE : The 8(R)-isomer of HPODE. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6438758 |
| CHEBI ID | 34485 |
| MeSH ID | M0204119 |
| Synonym |
|---|
| (8r,9z,12z)-8-hydroperoxyoctadeca-9,12-dienoic acid |
| CHEBI:34485 |
| (8r)-8-hydroperoxylinoleic acid |
| 8-hydroperoxylinoleic acid |
| (9z,12z)-(8r)-8-hydroperoxyoctadeca-9,12-dienoic acid |
| 8(r)-hpode |
| 143343-95-7 |
| 8r-hpode |
| LMFA02000113 |
| 8r-hydroperoxy-9z,12z-octadecadienoic acid |
| 9,12-octadecadienoic acid, 8-hydroperoxy-, (r-(z,z))- |
| 8-hpode |
| 8(r)-hydroperoxylinoleic acid |
| 8r-hydroperoxy-9z,12z-octadecadienoate |
| (r-(z,z))-8-hydroperoxy-9,12-octadecadienoic acid |
| (9z,12z)-(8r)-8-hydroperoxyoctadeca-9,12-dienoate |
| (r-(z,z))-8-hydroperoxy-9,12-octadecadienoate |
| 8r-hydroperoxylinoleic acid |
| Q27116103 |
| DTXSID101222963 |
| (8r,9z,12z)-8-hydroperoxy-9,12-octadecadienoic acid |
| Class | Description |
|---|---|
| HPODE | Hydroperoxy-octadecadienoic acids, formed in mammalian cells by peroxidation of linoleic acid. |
| octadecanoid | Unsaturated C18 fatty acids and skeletally related compounds. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||